Qtrex Quantum Ltd. · NASDAQ:QTEX
Qtrex Quantum — Inspira Technologies Oxy B.H.N. — IPO Roadshow (March 2021)
23 slides from Qtrex Quantum's IPO roadshow presentation, Mar 29, 2021
Slide 1: Breakthrough Oxygenation
Breakthrough Oxygenation March 2021 Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated March 29, 2021 Relating to Preliminary Prospectus dated March 29, 2021 Registration No. 333 - 253920 www.inspira - technologies.com
Slide 2: Free Writing Prospectus Statement
This presentation highlights basic information about us and the offering to which this presentation relates. Because it is a summary, it does not contain all of the information that you should consider before investing in our securities. The Company has filed a Registration Statement (including a pr
Slide 3: Forward-Looking Statements
This presentation of Inspira Technologies Oxy B.H.N. Ltd. (the “Company”) contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities law. Words such as “expects,” “intends,” “plans, ” “believes,” “seeks,” “estimates,” and similar e
Slide 4: Terms of the Offering
Terms of the Offering 4 Issuer Inspira Technologies Oxy B.H.N. Ltd. Offering Type Initial Public Offering Price Range $5.50 - $6.50 Shared Offered 2,750,000 shares plus 15%, 45 - day overallotment option Gross Proceeds $ 16.5 Million Listing/Symbol Nasdaq: IINN Pre - Offering Shares Outstanding 10,3
Slide 5: About Us: Vision
Vision Redefining Artificial Respiration to impact millions of lives We are a specialty medical device company developing proprietary respiratory support technology designed to prevent the need for mechanical ventilation, or MV, which is the current standard of care About Us 5 Proprietary - Inspira
Slide 6: Investment Highlights
Investment Highlights 6 • Innovative and cost - effective respiratory technology • Enables to avoid the use of MV, patients remain awake • Raises saturation levels in 1 minute • Reduces hospitalization days and device cost • Completed pre - clinical studies • Progressing to Verification & Safety Tri
Slide 7: A Large Respiratory Distress Market
A large Respiratory Distress Market 400M with a standard of care with significant disadvantages World population affected by respiratory insufficiency 20M ICU patients annually receive highly invasive mechanical ventilation 7 Proprietary - Inspira Technologies Oxy B.H.N. Ltd.
Slide 8: MV is a standard of care with significant disadvantages
MV is a standard of care with significant disadvantages Highly traumatic MV requires intrusive intubation & a medically induced coma: • Extended hospital stays leading to increased cost of care • Frequent incidence of infection • High mortality rates • Ventilation dependence 8 Proprietary - Inspira
Slide 9: Inspira Fills a Large Gap in Respiratory Treatment
Inspira Fills a Large Gap in Respiratory Treatment “Where supplemental therapies are insufficient & the risks of MV use are unjustified” Supplemental Oxygen mask therapies Augmented Respiration Technology Blood is oxygenated in awake, breathing patient Elevates saturation within 60+ secs* Mechanical
Slide 10: Expanding Respiratory Market Beyond the ICU
Expanding Respiratory Market Beyond the ICU Drivers • Increase in incidence & prevalence of respiratory disease • Rise of aged population • Increasing number of patients • Reducing of growing healthcare costs Market Ambulatory General Medical Units ICU 10 Proprietary - Inspira Technologies Oxy B.H.N
Slide 11: Augmented Respiratory Technology
Cannula draws blood at a low flow rate The ART oxygenates & removes CO 2 Blood returns to patient, raising saturation levels in 60 seconds Augmented Respiratory Technology ART provides respiratory support as the lungs rest and the patient is kept awake An easy & simple process 11 Proprietary - Inspi
Slide 12: Augmented Respiration Technology
Augmented Respiration Technology Intended Patient Patients requiring respiratory support, experiencing deteriorating saturation levels (Candidates for intubation & Mechanical Ventilation) Unique Alternative Clinicians can treat underlying respiratory problem while patient is awake & breathing sponta
Slide 13: Go-to-Market Strategy
Go - to - Market Strategy PHASE III Pursuing world - wide regulatory approvals PHASE I FDA/CE United States, Europe, Israel, Australia, China and Japan Collaborating with KOLs & hospitals PHASE II Expose ART system & attain both clinical endorsement and adoption of use in acute respiratory care Sale
Slide 14: Mechanical Ventilation vs ART
Mechanical Ventilation ART 500 Induced Coma Involves intubating patients whilst in an induced coma Patients are treated awake & mobile. No induced coma Hospital Days Requires long hospital stays. 40% have iatrogenic complications that extend treatment period Hospital days are expected to be reduced
Slide 15: Patents & Innovations
Patents & Innovations Method: Safe, easy to use without the need for a perfusionist Patent Intent of Use: Extracorporeal Oxygenation Method Component: Low impact radiography free dual lumen cannula Patent Name: Dual Lumen Cannula Component: Anti air - embolism, low - flow mechanism Patent Name: Adju
Slide 16: Regulatory Approval Process
Regulatory Approval Process* 2020 Filed several patents Studies performed on 200 - lb. swine models at C.R.O. facility Product design & performance validation Study protocol to be designed to demonstrate our ART system’s efficacy and reduced cost of treatment Planning studies with collaborating hosp
Slide 17: Preclinical Studies: Proven Results
Preclinical Studies: Proven Results Studies performed on 200 - lb. swine models at C.R.O. facility ART system used to provide temporary increase of oxygen gas exchange during respiratory failure by transferring clinically significant amounts of oxygen to the venous blood, while simultaneously extrac
Slide 18: A Fragmented Market
A Fragmented Market “ Filling the Gap in the Industry ” Breakthrough Oxygenation Respiratory Applications Blood Based Treatments Proprietary Low - flow Oxygenation Proprietary Cannula 18 * Trademarks are the property of their respective owners. Proprietary - Inspira Technologies Oxy B.H.N. Ltd.
Slide 19: Planned Key Milestones
Planned Key Milestones* Conditional Orders (Distribution) US Office Human Studies New Product FDA Submission Strategic Investment Strategic Partnership Verification & Safety Pre - market Early Adoption 19 *May be subject to change Proprietary - Inspira Technologies Oxy B.H.N. Ltd.
Slide 20: Reimbursement
Reimbursement Inspira plans to utilize existing CPT Codes using a “New Approach” to an existing procedure cms.gov: MS DRG based reimbursement for respiratory care Reduced Patient Complications Reduced Hospital Length of Stay & Re - admissions Reduced Costs & Operational Expenses Reduced Hospital & S
Slide 21: Recurring Revenue Model
Recurring Revenue Model Competitively priced system ART system is relatively small in size, which allows it to be used both in ICU and non - ICU settings, including hospital wards and ambulatory settings, without significant financial burden We are planning to sell an assembled product as well as it
Slide 22: Leadership
Leadership Urologic surgeon, inventor, entrepreneur & venture capital investor Vast experience in leading high growth, publicly traded medical companies Co - founded Vidamed Inc., acquired by Medtronic Inc. (NYSE: MDT) Co - founded Medinol , partnered with Boston Scientific (NYSE: BSX) Former CFO, C
Slide 23: Thank You
Thank You Joe Hayon Co - Founder, President & CFO E - mail : joe@inspirao2.com www.inspira - technologies.com
Inspira Technologies Oxy B.H.N. — IPO Roadshow (March 2021) on 6ix